CN113521090A - Anti-aging composition, medicine and health product containing anti-aging composition, and application of anti-aging composition - Google Patents
Anti-aging composition, medicine and health product containing anti-aging composition, and application of anti-aging composition Download PDFInfo
- Publication number
- CN113521090A CN113521090A CN202010317054.6A CN202010317054A CN113521090A CN 113521090 A CN113521090 A CN 113521090A CN 202010317054 A CN202010317054 A CN 202010317054A CN 113521090 A CN113521090 A CN 113521090A
- Authority
- CN
- China
- Prior art keywords
- aging composition
- aging
- adenosylmethionine
- amount
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 230000036541 health Effects 0.000 title claims abstract description 15
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical class O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims abstract description 42
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical class NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 claims abstract description 41
- 229960001570 ademetionine Drugs 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 229940032147 starch Drugs 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- LJOHERYEBSTHSF-WXLUKGNWSA-N [(3S)-3-amino-3-carboxypropyl]-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-methylsulfanium 4-methylbenzenesulfonate sulfate Chemical compound C1(=CC=C(C=C1)S(=O)(=O)[O-])C.S(=O)(=O)([O-])[O-].N[C@@H](CC[S+](C[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3N)O1)O)O)C)C(O)=O.N[C@@H](CC[S+](C[C@@H]1[C@H]([C@H]([C@H](N3C=NC2=C3N=CN=C2N)O1)O)O)C)C(O)=O.N[C@@H](CC[S+](C[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3N)O1)O)O)C)C(O)=O LJOHERYEBSTHSF-WXLUKGNWSA-N 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 229960000913 crospovidone Drugs 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- NWVICASORGOGDW-FFSFXTILSA-N [(3s)-3-amino-3-carboxypropyl]-[[(2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-methylsulfanium;butane-1,4-disulfonate Chemical compound [O-]S(=O)(=O)CCCCS([O-])(=O)=O.O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1.O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 NWVICASORGOGDW-FFSFXTILSA-N 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 5
- 239000008109 sodium starch glycolate Substances 0.000 claims description 5
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 2
- HRRKROCHQWEMKS-HFSAJWEPSA-N S([O-])(O)(=O)=O.S(=O)(=O)([O-])C1=CC=C(C)C=C1.[C@@H]1([C@H](O)[C@H](O)[C@@H](C[S+](CC[C@H](N)C(=O)O)C)O1)N1C=NC=2C(N)=NC=NC12.[C@@H]1([C@H](O)[C@H](O)[C@@H](C[S+](CC[C@H](N)C(=O)O)C)O1)N1C=NC=2C(N)=NC=NC12 Chemical compound S([O-])(O)(=O)=O.S(=O)(=O)([O-])C1=CC=C(C)C=C1.[C@@H]1([C@H](O)[C@H](O)[C@@H](C[S+](CC[C@H](N)C(=O)O)C)O1)N1C=NC=2C(N)=NC=NC12.[C@@H]1([C@H](O)[C@H](O)[C@@H](C[S+](CC[C@H](N)C(=O)O)C)O1)N1C=NC=2C(N)=NC=NC12 HRRKROCHQWEMKS-HFSAJWEPSA-N 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 4
- 230000008092 positive effect Effects 0.000 abstract description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 4
- 102000000344 Sirtuin 1 Human genes 0.000 abstract description 3
- 108010041191 Sirtuin 1 Proteins 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 description 18
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 229910001220 stainless steel Inorganic materials 0.000 description 7
- 239000010935 stainless steel Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 229950006238 nadide Drugs 0.000 description 6
- 229960003966 nicotinamide Drugs 0.000 description 6
- 235000005152 nicotinamide Nutrition 0.000 description 6
- 239000011570 nicotinamide Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- JRYYVMDEUJQWRO-UHFFFAOYSA-N 2-methylnicotinamide Chemical compound CC1=NC=CC=C1C(N)=O JRYYVMDEUJQWRO-UHFFFAOYSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VHPOFDUCFKOUHV-XKGORWRGSA-N (2s)-2-amino-4-[[(2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylsulfonio]butanoate;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VHPOFDUCFKOUHV-XKGORWRGSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 108010088865 Nicotinamide N-Methyltransferase Proteins 0.000 description 2
- 102000009063 Nicotinamide N-methyltransferase Human genes 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- VERAMNDAEAQRGS-UHFFFAOYSA-N butane-1,4-disulfonic acid Chemical class OS(=O)(=O)CCCCS(O)(=O)=O VERAMNDAEAQRGS-UHFFFAOYSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an anti-aging composition, a medicine and a health product containing the same, and application thereof. The active ingredients of the anti-aging composition are salts of nicotinamide mononucleotide and S-adenosylmethionine, and the molar ratio of the nicotinamide mononucleotide to the salt of S-adenosylmethionine is 1 (0.2-3.0). The compositions of the present invention can reduce or eliminate the accumulation of NAM while providing adequate anti-aging benefits. In addition, the composition of the invention has good safety, can also improve the level of longevity protein (Sirt1) and can bring positive effects on insulin resistance and height body mass index.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to an anti-aging composition, a medicine and a health product containing the same, and application thereof.
Background
Nicotinamide Mononucleotide (NMN) is an inherent substance in the human body. In humans, NMN is intracellular Nicotinamide Adenine Dinucleotide (NAD)+) By NAD+Is shown. NAD (nicotinamide adenine dinucleotide)+The coenzyme I is also called coenzyme I, is the coenzyme of hundreds of oxidation-reduction reactions, and has the functions of catalyzing and generating more than 95 percent of energy required by life activities and regulating hundreds of metabolic reactions of human bodies. Scientific research in recent years has further revealed that NAD is a coenzyme for hundreds of enzymes+Is also key to maintain 7 longevity proteins, repair DNA and maintain the normal function of immune system. NMN has important physiological functions for human cells, can be naturally synthesized in the cells, and can also be derived from various foods, including broccoli, cabbage, cucumber, green soybean, avocado, and the like.
After middle age, NAD+The amount of the compound is sharply reduced to only a fraction of the number of young people, thereby triggering various symptoms of aging in the body, such as memory deterioration, cardiovascular function weakening, immunity disorder, poor sleep quality, energy decline, blood sugar increase, constipation, alopecia, anorexia, and degeneration of various neurons. Scientists repeatedly demonstrated that NMN supplementation can effectively increase and restore NAD in vivo+And (4) horizontal.
However, NMN is converted to Nicotinamide (NAM), a metabolite, after use and accumulates in the body, giving rise to the opportunity to induce liver fibrosis or fatty liver.
Disclosure of Invention
In order to solve the problems in the prior art, the present invention provides an anti-aging composition, a medicine and a health product comprising the same, and applications thereof.
Specifically, the present invention provides:
(1) an anti-aging composition, characterized in that the active ingredient of the anti-aging composition is a salt of nicotinamide mononucleotide and S-adenosylmethionine, and wherein the molar ratio of nicotinamide mononucleotide to the salt of S-adenosylmethionine is 1 (0.2-3.0).
(2) The anti-aging composition according to (1), wherein the salt of S-adenosylmethionine is selected from one or more of S-adenosylmethionine p-toluenesulfonic acid sulfate, S-adenosylmethionine 1, 4-butanedisulfonate.
(3) The anti-aging composition of (1), wherein the amount of nicotinamide mononucleotide is 5% -20% (w/w) based on the total weight of the anti-aging composition.
(4) The anti-aging composition according to (1), wherein the amount of the salt of S-adenosylmethionine is 9-65% (w/w) based on the total weight of the anti-aging composition.
(5) The antiaging composition according to (2), wherein the sulfate salt of S-adenosylmethionine p-toluene sulfonic acid is in an amount of 9% to 35% (w/w) and the 1, 4-butanedisulfonate salt of S-adenosylmethionine is in an amount of 18% to 65% (w/w), based on the total weight of the antiaging composition.
(6) The anti-aging composition of (1), wherein the anti-aging composition further comprises an adjuvant.
(7) The antiaging composition according to (6), wherein the auxiliary is selected from one or more of a filler, a disintegrant, a lubricant, and a coating agent.
(8) The anti-aging composition according to (7), wherein the filler is selected from one or more of microcrystalline cellulose, lactose, starch, mannitol, and the amount of the filler is 10% to 70% (w/w) based on the total weight of the anti-aging composition.
(9) The antiaging composition of (7), wherein the disintegrant is selected from one or more of croscarmellose sodium, crospovidone, sodium starch glycolate, and the amount of the disintegrant is 0.5% to 5% (w/w) based on the total weight of the antiaging composition.
(10) The anti-aging composition according to (7), wherein the lubricant is selected from one or more of magnesium stearate, aerosil, talc and the amount of the lubricant is 0.1% to 3% (w/w) based on the total weight of the anti-aging composition.
(11) The anti-aging composition of (1), wherein the anti-aging composition comprises a dose of 1-5000 mg/day of the nicotinamide mononucleotide.
(12) The anti-aging composition according to (1), wherein the anti-aging composition comprises the salt of S-adenosylmethionine at a dose of 1-5000 mg/day.
(13) Use of the anti-aging composition according to any one of (1) to (12) for the preparation of an anti-aging medicament or health product.
(14) An anti-aging drug comprising the anti-aging composition of any one of (1) to (12).
(15) The antiaging agent according to (14), wherein the antiaging agent is in the form of an oral preparation or an injection; wherein the oral preparation comprises tablets, capsules, granules, powders and liquid preparations; preferably, the oral formulation is an enteric formulation.
(16) An anti-aging health product comprising the anti-aging composition of any one of (1) to (12).
(17) The anti-aging health product according to (16), wherein the anti-aging health product is in the form of an oral preparation; wherein the oral preparation comprises tablets, capsules, granules, powders and liquid preparations; preferably, the oral formulation is an enteric formulation.
Compared with the prior art, the invention has the following advantages and positive effects:
the invention provides a novel anti-aging combination and application thereof, and provides that S-adenosylmethionine salt is simply added into NMN, and the molar ratio of 1 (0.2-3.0) is satisfied, so that enough methyl source can be provided for decomposition of the NMN, accumulation of NAM is reduced or solved, and sufficient anti-aging effect can be provided.
The salt of NMN and S-adenosylmethionine has good safety when being used as a medicine or a health care product.
The invention can also improve the level of longevity protein (Sirt1) and bring positive effects to insulin resistance and body height and body mass index.
Detailed Description
The present invention is further described in the following description of the specific embodiments, which is not intended to limit the invention, but various modifications and improvements can be made by those skilled in the art according to the basic idea of the invention, within the scope of the invention, as long as they do not depart from the basic idea of the invention.
In order to solve the problem of accumulation of NAM in the body caused by NMN, the present invention proposes to simply add a salt of S-adenosylmethionine to NMN and satisfy a molar ratio of 1 (0.2-3.0).
Accordingly, the present invention provides a novel anti-aging composition characterized in that the active ingredient of the anti-aging composition is a salt of nicotinamide mononucleotide and S-adenosylmethionine, and wherein the molar ratio of nicotinamide mononucleotide to the salt of S-adenosylmethionine is 1 (0.2-3.0).
Salts of S-adenosylmethionine exist in humans as S-adenosylmethionine (SAMe). SAMe carries an activated methyl group and is the major coenzyme involved in the transmethylation reaction, and after the activated methyl group is lost, SAMe becomes S-adenosyl-L-homocysteine (SAH). Most SAMe in the human body is produced mainly in the liver, where it is involved in over 40 chemical reactions of anabolism or catabolism. While its precursor methionine (methionine) is abundant in many protein diets, SAMe is not sufficient in the diet. SAMe is synthesized from methionine by the liver, but methionine supplementation does not effectively increase the amount of SAMe synthesized by the body. It was found that regular consumption of SAMe could combat depression, liver disease, and arthritis/joint pain. SAMe is sold in the US market under the name of a nutritional supplement, and has the effects of improving mood, protecting the liver and comforting the joints. As the number of nutritional supplements increases in mass consumption, the SAMe for therapeutic purposes also increases.
The present invention is not bound by theory, but it is believed that NAM is converted into Methylnicotinamide (MNA) by the methyl transfer reaction of SAMe using Nicotinamide N-methyltransferase (NNMT) in the human body and excreted.
In addition, MNA can induce an increase in the level of longevity protein (Sirt1) and a synergistic effect with NMN. In addition, MNA also has a positive effect on insulin resistance (insulin resistance) and Body Mass Index (BMI).
When the molar ratio of nicotinamide mononucleotide to the salt of S-adenosylmethionine is less than 1:3.0, the upper recommended daily dosage of S-adenosylmethionine is easily exceeded; when the molar ratio of nicotinamide mononucleotide to the salt of S-adenosylmethionine is greater than 1:0.2, NAM begins to accumulate in the body, possibly inducing diseases such as non-alcoholic fatty liver, hepatitis or liver cirrhosis.
Preferably, the amount of nicotinamide mononucleotide is 5% to 20% (w/w) based on the total weight of the anti-aging composition.
Preferably, the amount of the salt of S-adenosylmethionine is 9-65% (w/w), preferably 9-35% (w/w) or 18-65% (w/w), based on the total weight of the anti-aging composition.
Preferably, the sulfate salt of S-adenosylmethionine p-toluene sulfonic acid is in an amount of 9% to 35% (w/w) based on the total weight of the anti-aging composition.
Preferably, the amount of S-adenosylmethionine 1, 4-butanedisulfonate is 18% -65% (w/w) based on the total weight of the anti-aging composition
In some embodiments of the invention, the anti-aging composition further comprises an adjuvant. The auxiliary material can be one or more selected from bulking agent, disintegrating agent, lubricant and coating agent.
The filler may be selected from one or more of microcrystalline cellulose, lactose, starch, mannitol. The amount of the filler may be 10% to 70% (w/w) based on the total weight of the anti-aging composition.
The disintegrant is selected from one or more of croscarmellose sodium, crospovidone and carboxymethyl starch sodium. The amount of the disintegrant may be from 0.5% to 5% (w/w) based on the total weight of the anti-aging composition.
The lubricant is selected from one or more of magnesium stearate, silica gel micropowder and talcum powder. The lubricant may be present in an amount of 0.1% to 3% (w/w) based on the total weight of the anti-aging composition.
The daily dosage of nicotinamide mononucleotide is preferably 1-5000 mg/day, more preferably 300-3000 mg/day, and still more preferably 600-1500 mg/day.
Thus, the anti-aging composition of the present invention may comprise nicotinamide mononucleotide at a dose of 1-5000 mg/day, or nicotinamide mononucleotide at a dose of 300-3000 mg/day, or nicotinamide mononucleotide at a dose of 600-1500 mg/day.
The daily dosage of the salt of S-adenosylmethionine is 1-5000 mg/day, more preferably 400-4000 mg/day, and still more preferably 800-3200 mg/day.
Thus, the anti-aging composition of the present invention may comprise a salt of S-adenosylmethionine at a dose of 1-5000 mg/day, or a salt of S-adenosylmethionine at a dose of 400-4000 mg/day, or a salt of S-adenosylmethionine at a dose of 800-3200 mg/day.
Preferably, nicotinamide mononucleotide is present in the single-dose pharmaceutical composition in an amount of 100-150mg and the salt of S-adenosylmethionine is present in the single-dose pharmaceutical composition in an amount of 30-300mg, e.g. 150 mg.
The invention also provides application of the anti-aging composition in preparation of anti-aging drugs or health care products.
The invention also provides an anti-aging medicament which comprises the anti-aging composition. Preferably, the anti-aging drug is in the form of an oral formulation or an injection. The oral preparation comprises solid preparations such as tablets, capsules (such as soft capsules), granules, powder and the like, and liquid preparations, and preferably, the oral preparation is an enteric preparation.
In the present invention, the dosage form may be prepared from the pharmaceutical composition of the present invention by a method known in the art using known materials.
In a preferred embodiment of the invention, the anti-aging drug is a tablet and the amount of nicotinamide mononucleotide present in the single tablet is 100-150mg and the amount of the salt of S-adenosylmethionine present in the single tablet is 30-300mg, e.g. 150 mg.
The invention also provides an anti-aging health product which comprises the anti-aging composition. Preferably, the anti-aging health product is in the form of an oral preparation; wherein the oral preparation comprises solid preparation such as tablet, capsule (such as soft capsule), granule, powder, etc., and liquid preparation; preferably, the oral formulation is an enteric formulation.
In the present invention, the dosage form may be prepared from the pharmaceutical composition of the present invention by a method known in the art using known materials.
In a preferred embodiment of the present invention, the anti-aging health product is a tablet, and the amount of nicotinamide mononucleotide in the single-dose tablet is 100-150mg, and the amount of salt of S-adenosylmethionine in the single-dose tablet is 30-300mg, for example 150 mg.
The present disclosure is further illustrated or described below by way of examples, which should not be construed as limiting the scope of the invention.
Examples
The following examples, unless otherwise indicated, are carried out using conventional procedures, materials and conditions in the art or as recommended by the manufacturer.
The materials and equipment used in the examples are described below
Food grade β -nicotinamide mononucleotide (white dry powder; purity > 99%): produced by GenBank harbor Biotechnology Ltd (Gene harbor (hong Kong)) Biotechnologies Ltd;
food grade S-adenosylmethionine p-toluenesulfonate sulfate: a white dry powder; purity > 99%): produced by Gene harbor (hong Kong) Biotechnology Ltd (Gene harbor (hong Kong) Biotechnologies Ltd).
Food grade S-adenosylmethionine 1, 4-butanedisulfonate: a white dry powder; purity > 98%): produced by Gene harbor (hong Kong) Biotechnology Ltd (Gene harbor (hong Kong) Biotechnologies Ltd).
Example 1
(1) Weighing: 16g food grade NMN; 7.6g food grade S-adenosylmethionine p-toluenesulfonate sulphate; 15g D-mannitol; 30g of starch; 10g of microcrystalline cellulose; 3.5g crospovidone; 0.5g of silica gel micropowder;
(2) stirring in stainless steel container, adding 0.5g magnesium stearate, mixing, and tabletting.
Example 2
(1) Weighing: 7g food grade NMN; 8.1g food grade S-adenosylmethionine p-toluenesulfonate sulphate; 12g of lactose; 10g of starch; 2g of sodium starch glycolate; 0.8g microcrystalline cellulose; 0.5g of silica gel micropowder;
(2) stirring in stainless steel container, adding 0.5g magnesium stearate, mixing, and tabletting.
Example 3
(1) Weighing: 7g food grade NMN; 8.1g food grade S-adenosylmethionine p-toluenesulfonate sulphate; 12g of lactose; 10g of starch; 1g of sodium starch glycolate; 0.5g of silica gel micropowder;
(2) stirring in stainless steel container, adding 0.5g magnesium stearate, mixing, and tabletting.
Example 4
(1) Weighing: 3.3g food grade NMN; 22.5g food grade S-adenosylmethionine p-toluenesulfonate sulphate; 13g D-mannitol; 20g of starch; 2.5g crospovidone; 0.5g of silica gel micropowder;
(2) stirring in stainless steel container, adding 0.5g magnesium stearate, mixing, and tabletting.
Example 5
(1) Weighing: 5g food grade NMN; 17.2g food grade S-adenosylmethionine p-toluenesulfonate sulphate; 15g D-mannitol; 30g of starch; 10g of microcrystalline cellulose; 3.5g crospovidone; 1.5g of silica gel micropowder;
(2) stirring in stainless steel container, adding 0.5g magnesium stearate, mixing, and tabletting.
Example 6
(1) Weighing: 7g food grade NMN; 8.1g food grade S-adenosylmethionine p-toluenesulfonate sulphate; 12g of lactose; 10g of starch; 2g of sodium starch glycolate; 0.8g microcrystalline cellulose; 0.5g of silica gel micropowder;
(2) stirring uniformly in a stainless steel container, adding 0.5g of magnesium stearate, and mixing uniformly;
(3) capsules were coated with 2.5 grams of barrier coating (2.4g hypromellose and 0.1g polyethylene glycol) and 7.3 grams of enteric coating (6.2g yutechi and 1.1g talc).
Example 7
(1) Weighing: 19g food grade NMN; 17g food grade S-adenosylmethionine 1, 4-butanedisulfonate; 8g D-mannitol; 30g of starch; 15g of microcrystalline cellulose; 3.5g crospovidone; 1.5g of silica gel micropowder;
(2) stirring in stainless steel container, adding 0.5g magnesium stearate, mixing, and tabletting.
Claims (17)
1. An anti-aging composition, characterized in that the active ingredient of the anti-aging composition is a salt of nicotinamide mononucleotide and S-adenosylmethionine, and wherein the molar ratio of nicotinamide mononucleotide to the salt of S-adenosylmethionine is 1 (0.2-3.0).
2. The anti-aging composition according to claim 1, wherein the salt of S-adenosylmethionine is selected from one or more of S-adenosylmethionine p-toluenesulfonate sulfate, S-adenosylmethionine 1, 4-butanedisulfonate.
3. The anti-aging composition of claim 1, wherein the amount of nicotinamide mononucleotide is from 5% to 20% (w/w) based on the total weight of the anti-aging composition.
4. The anti-aging composition according to claim 1, wherein the amount of the salt of S-adenosylmethionine is 9% -65% (w/w) based on the total weight of the anti-aging composition.
5. The anti-aging composition according to claim 2, wherein the amount of S-adenosylmethionine p-toluenesulfonic acid sulfate is 9% to 35% (w/w) and the amount of S-adenosylmethionine 1, 4-butanedisulfonate is 18% to 65% (w/w), based on the total weight of the anti-aging composition.
6. The anti-aging composition of claim 1, wherein the anti-aging composition further comprises an adjuvant.
7. The anti-aging composition according to claim 6, wherein the adjuvant is selected from one or more of a filler, a disintegrant, a lubricant, a coating agent.
8. The anti-aging composition according to claim 7, wherein the filler is selected from one or more of microcrystalline cellulose, lactose, starch, mannitol, and is present in an amount of 10% to 70% (w/w) based on the total weight of the anti-aging composition.
9. The anti-aging composition according to claim 7, wherein the disintegrant is selected from one or more of croscarmellose sodium, crospovidone, sodium starch glycolate, and the amount of the disintegrant is from 0.5% to 5% (w/w) based on the total weight of the anti-aging composition.
10. The anti-aging composition according to claim 7, wherein the lubricant is selected from one or more of magnesium stearate, aerosil, talc and is in an amount of 0.1% to 3% (w/w) based on the total weight of the anti-aging composition.
11. The anti-aging composition of claim 1, wherein the anti-aging composition comprises a dose of 1-5000 mg/day of the nicotinamide mononucleotide.
12. The anti-aging composition according to claim 1, wherein the anti-aging composition comprises the salt of S-adenosylmethionine at a dose of 1-5000 mg/day.
13. Use of the anti-aging composition according to any one of claims 1 to 12 for the preparation of an anti-aging medicament or health product.
14. An anti-aging medicament comprising the anti-aging composition of any one of claims 1-12.
15. The anti-aging medication according to claim 14, wherein the anti-aging medication is in the form of an oral preparation or an injection; wherein the oral preparation comprises tablets, capsules, granules, powders and liquid preparations; preferably, the oral formulation is an enteric formulation.
16. An anti-aging nutraceutical comprising the anti-aging composition of any one of claims 1-12.
17. The anti-aging nutraceutical of claim 16, wherein the anti-aging nutraceutical is in the form of an oral formulation; wherein the oral preparation comprises tablets, capsules, granules, powders and liquid preparations; preferably, the oral formulation is an enteric formulation.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010317054.6A CN113521090A (en) | 2020-04-21 | 2020-04-21 | Anti-aging composition, medicine and health product containing anti-aging composition, and application of anti-aging composition |
| PCT/CN2021/077542 WO2021212995A1 (en) | 2020-04-21 | 2021-02-24 | Anti-ageing composition, drug and healthcare product comprising same, and application therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010317054.6A CN113521090A (en) | 2020-04-21 | 2020-04-21 | Anti-aging composition, medicine and health product containing anti-aging composition, and application of anti-aging composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113521090A true CN113521090A (en) | 2021-10-22 |
Family
ID=78093813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010317054.6A Pending CN113521090A (en) | 2020-04-21 | 2020-04-21 | Anti-aging composition, medicine and health product containing anti-aging composition, and application of anti-aging composition |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113521090A (en) |
| WO (1) | WO2021212995A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115227705A (en) * | 2022-08-01 | 2022-10-25 | 成都川宇健维生物科技有限公司 | Application of beta-nicotinamide mononucleotide in preparation of medicine for preventing and/or treating constipation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201802933YA (en) * | 2015-10-07 | 2018-05-30 | Joel Huizenga | Resetting biological pathways for defending against and repairing deterioration from human aging |
-
2020
- 2020-04-21 CN CN202010317054.6A patent/CN113521090A/en active Pending
-
2021
- 2021-02-24 WO PCT/CN2021/077542 patent/WO2021212995A1/en active Application Filing
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115227705A (en) * | 2022-08-01 | 2022-10-25 | 成都川宇健维生物科技有限公司 | Application of beta-nicotinamide mononucleotide in preparation of medicine for preventing and/or treating constipation |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021212995A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1103593C (en) | Synergistic combination of zidovudine | |
| CN101278928B (en) | Medicament composition containing levocarnitine or its derivatives and use thereof | |
| JP2002512979A (en) | Homogeneous pharmaceutical composition comprising abaca beer, lamivudine and zidovudine | |
| JP5114399B2 (en) | Drugs for fatigue prevention and / or recovery | |
| CN113521090A (en) | Anti-aging composition, medicine and health product containing anti-aging composition, and application of anti-aging composition | |
| KR100861430B1 (en) | Preparations and Method of Producing the Same | |
| AU742460B2 (en) | Fatty acids as a diet supplement | |
| US11160820B2 (en) | Pharmaceutical use of argininyl fructosy glucose | |
| US6509035B1 (en) | Oral preparation of coenzyme a useful for lowering blood lipid and a method producing for same | |
| CN102755310B (en) | A kind of composition medicine preparation containing levodopa | |
| CN111202731B (en) | Combined application, medicinal composition and application thereof | |
| CN101658519A (en) | Medicinal composition for treating hyperuricemia | |
| KR20190046675A (en) | A pharmaceutical composition for the preventing and treating a liver disease | |
| KR102483142B1 (en) | Multi-vitamins complex composition with improved compliance through size reduction for formulation using iLet(innovative Low excipient tablet) technology and preparation method for the same | |
| CN101780091B (en) | Medical composition containing ivabradine and ranolazine | |
| JPH07118148A (en) | Preventive for hepatoma | |
| TW200824676A (en) | Cardiovascular drug | |
| JP2011068647A (en) | Solid formulation containing aspartic acid or salt thereof | |
| EP1741431A1 (en) | The combination for treating hyperlipemia | |
| JP2005154281A (en) | Medicinal composition for prophylaxis and therapy of arthropathy | |
| US20030004130A1 (en) | Homogeneous pharmaceutical compositions containing zidovudine and lamivudine | |
| CN111643490B (en) | Pharmaceutical composition with maltose hydrolase inhibition activity and application thereof | |
| CN101062047B (en) | Combination including isoglycyrrhizinate and oxymatrine and the purpose thereof | |
| CN109381476B (en) | Weight-losing pharmaceutical composition | |
| CN101428012B (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |